Kornimate/medical-research-clean huggingface dataset:
acceptance and performance of the cp1170 sound processor in experienced adult cochlear implant recipients (polar)

Conditions: Hearing Impairment

Summary: acceptance and performance of the cp1170 sound processor in experienced adult cochlear implant recipients compared with the cp1150 sound processor and their current sound processor.

this investigation is planned to investigate the performance and clinical benefits of features that are new to the cp 1170 sound processor. this study will build on the evidence previously collected on ote (off the ear) sound processors and forwardfocus, with particular focus on the acceptance and satisfaction of the automation of forwardfocus in the cp1170 sound processor and associated components in general.

Eligibility criteria:
inclusion criteria: 1. aged 18 years or older 2. post lingually deafened 3. implanted with the ci600 series (ci612, ci632, ci622, ci624), ci500 series (ci512, ci532, ci522); freedom series (ci24re(ca), ci24re(st), ci422) or n24 series (cic3). 4. at least 6 months experience with a cochlear hearing implant 5. at least 3 months experience with any nucleus sound processor and scan program 6. able to score 30% or more at +15 snr with ci alone on a sentence in babble test 7. willingness to participate in and to comply with all requirements of the protocol 8. fluent speaker in english as determined by the investigator 9. willing and able to provide written informed consent. exclusion criteria: 1. additional disabilities that would prevent participation in evaluations 2. unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedures 3. unable or unwilling to comply with the requirements of the clinical investigation as determined by the investigator 4. investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling 5. cochlear employees or employees of contract research organisations or contractors engaged by cochlear for the purposes of this investigation, as determined by the investigator. 6. current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless the other investigation was/is a cochlear sponsored investigation and determined by the investigator or sponsor to not impact this investigation).
paravertebral catheters for vats procedures

Conditions: Acute Pain

Summary: level i randomized prospective outcomes study comparing two groups of patients. one group will receive dilaudid patient controlled analgesia (pca) post-operatively. the other will receive an ultrasound guided paravertebral block with indwelling paravertebral catheter with an infusion of 0.2% ropivicaine post-operatively and a pca.

design: level i randomized prospective outcomes study comparing two groups of patients. one group will receive dilaudid patient controlled analgesia (pca) post-operatively. the other will receive an ultrasound guided paravertebral block with indwelling paravertebral catheter with an infusion of 0.2% ropivicaine post-operatively and a pca. sample size: 50 patients study duration: approximately 24 months population:. patients presenting to the university of minnesota medical center for elective video assisted thoracoscopic surgery (vats), for thoracic, lung, or mediastinal lesions or masses. primary objective: to determine if post-operative paravertebral catheters in patients with elective vats procedures result in decreased pain compared to patients treated with pca for post-operative pain. secondary objectives: 1. to determine whether the use of paravertebral catheters impacts the length of icu and hospital stay for patients, compared to a pca in patients undergoing elective video assisted thoracoscopic surgery (vats). 2. to determine whether the use of paravertebral catheters leads to lower risk of complications, compared to use of a pca in patients undergoing elective video assisted thoracoscopic surgery (vats). 2. synopsis and medical application: specific aims: primary hypothesis: paravertebral catheters will result in improved pain control relative to pca for post-operative pain from thoracic surgery. secondary hypothesis: paravertebral catheters will result in fewer hospital days and improved subjective respiratory function compared to patients in the pca group.

Eligibility criteria:
inclusion criteria: * • all patients undergoing elective vats. exclusion criteria: * • previous difficult airway or multiple previous intubations * history of myasthenic syndrome * systemic infection * pre-existing sensory deficit * pt \>14 or ptt \>40 sec * platelet count less than 50,000 * creatinine \> 1.5 * allergy to local anesthetics * patients who remain intubated for one week after surgery or who are unable to provide information as to their feelings of pain post-operatively for the first week post-operatively * use of a spinal or epidural anesthetic for surgery * daily use of opioid for more than a week * lack of patient cooperation * contraindication to regional anesthesia * infection at injection site * inability to guarantee sterile equipment or sterile conditions for the block * patient refusal * risk of local anesthetic toxicity * coagulopathy or bleeding disorder * severe respiratory disease (where the patient depends on intercostal muscle function for ventilation); * ipsilateral diaphragmatic paresis; * severe spinal deformities (kyphosis or scoliosis) * previous thoracotomy
acute kidney injury and renal outcomes for covid-19 patients in intensive care units

Conditions: on Occurrence of Acurate Kidney Injury During Intensive Care Unit; Abnormalities of Urinary Analysis

Summary: the actual covid-19 epidemy is an unprecedented healthcare problem. although acute respiratory distress syndrome is the main organ failure, acute kidney injury (aki) has appeared to be more frequent and more severe than expected. some data suggested a potential direct renal tropism of the virus, or undirect injury by "cytokine storm". the aims of this study are: 1. to describe incidence, severity and mortality associated with aki during covid-19 infection in icu 2. to identify specific risk factors for aki 3. to explore pathophysiologic mechanism of aki during covid-19 infection


Eligibility criteria:
inclusion criteria: * confirmed covid-19 infection (by qrt-pcr and/or tdm typical lesion) * needing intensive care exclusion criteria: * end stage renal disease patients (with pre-existent dialysis) * intensive care support for less than 72h (transfer in conventional unit or death)

Keywords: acurate kidney injury
search for biological markers of orosensory perception of fatty acids in healthy subjects and possible modifications in patients with type 2 diabetes and in obese non-diabetic patients.

Conditions: Type 2 Diabetes or Obesity Without Diabetes

Summary: animal studies have shown that stimulation of the lingual lipid-receptor, cd 36, is accompanied by the rapid secretion of hormones in the digestive tract (incretines). we aim to determine in healthy humans whether the orosensory perception of fatty acids is followed by a modification in plasma levels of digestive tract hormones (cholecystokinin, gip, glp-1, secretin, pancreatic peptide, peptide yy, insulin) and metabolic markers from adipose tissue (leptin, ghrelin, adiponectin). we also aim to determine whether the hormonal response induced by orosensory stimulation by lipids is modified: * in patients with type 2 diabetes * in obese non-diabetic patients we expect to show an increase in biological markers biological, and more particularly in certain digestive hormones such as pancreatic polypeptide, gip, glp-1...after stimulation of the lingual lipid receptor, cd36. we will also determine whether or not this response is modified in patients with type 2 diabetes and in obese non-diabetic patients. we also wish to measure the subjects' gustatory detection threshold for a fatty acid (linoleic acid), and to determine whether there is a relationship between the orosensory perception threshold for linoleic acid and the physiological status of the subjects. in order to achieve this, the thresholds for healthy subjects will be compared with thresholds for obese and diabetic subjects. expected results: the threshold of detection for linoleic acid in healthy subjects will be lower than that in obese or diabetic patients.


Eligibility criteria:
inclusion criteria: * persons who have provided written consent * healthy volunteers: * men \> 18 years * 19 \<bmi \< 25 kg.m-2 * fasting triglyceridemia \< 1.50 g/l * fasting glycemia \< 1.10 g/l * without regular medical treatment * patients with type-2 diabetes: * men \>18 years * type 2 diabetes (fasting glycemia \> 7 mmol/l at the diagnosis) treated with diet or diet + oral antidiabetics (metformin, and/or insulinsecretion agents \[hypoglycemic sulphonamides, or glinides\] and/or glitazones and/or acarbose) * stable oral antidiabetic treatment for 3 months * obese non-diabetic patients: * men \> 18 years * bmi 30 kg.m-2 * fasting glycemia \< 1.10 g/l * hba1c \< 6.0% * absence of treatment with hypoglycemic agents (including benfluorex) * absence of medical treatment for obesity * absence of a history of surgery for obesity (band, by-pass) or gastric stimulator (type tantalus) exclusion criteria: * persons not covered by the national health insurance * smokers, or smoking cessation within the 3 months preceding inclusion * persons with eating disorders: * severe digestive disease (enteropathy with absorption disorders, inflammatory digestive disease) * pancreatic insufficiency * history of pancreas surgery * type 1 diabetes * renal insufficiency * hepatic insufficiency * treatment with proton pump inhibitors, insulin, glp-1 analogues, dpp-4 inhibitors
group intervention on executive function in children with autism spectrum disorder

Conditions: Autism Spectrum Disorder; Autism

Summary: autism is a developmental disorder characterized by difficulties in social communication, repetitive behaviors, and social interaction. a key aspect of autism concerns executive functions, which are a set of cognitive processes that regulate attention, planning, inhibition, and impulse control. these functions are often impaired in children with autism, affecting their learning and daily functioning. the present protocol aims to test the first absolute and then comparative effectiveness of two executive function development programs: the "apismela" training and the "unstuck \& on target! second edition". two groups will be held at the same time and will conduct the two programs in reverse order. in fact, the protocol is divided into two phases. participants subjected to the apismela group, finished the intervention sessions will conduct an interim evaluation and then begin the intervention phases of the unstuck \& on target! second edition protocol. participants subjected to the unstuck \& on target! second edition group, finished the intervention sessions will conduct an interim evaluation and then begin the intervention phases of the apismela protocol. group intervention programs were chosen for two reasons: group intervention compared with individual intervention have lower costs for patients and their families and thus higher overall social acceptability. the second is that group intervention within the social-constructivist paradigm, to which the two chosen programs belong, becomes a fundamental resource for stimulating that augmentative learning that is a source of development on the cognitive and conceptual levels for human beings.


Eligibility criteria:
inclusion criteria: * children with diagnosis of autism and autism spectrum disorder exclusion criteria: * presence of other medical disorders

Keywords: autism children executive functions
perceptions of passive heating in individuals with t2dm

Conditions: Type 2 Diabetes

Summary: current treatments for type 2 diabetes (e.g., lifestyle changes and clinical interventions such as medication), have been shown to be unsustainable due to low levels of physical activity and increasing clinical costs. therefore, scientists have been looking for new treatments to address this issue. one such treatment that is being investigated is passive heating (e.g., hot baths, saunas, etc.). in this study the investigators want to ascertain what passive heating, if any, individuals with t2dm currently do, what their perceptions of passive heating would be if it were to become a treatment, what may make it easier or more difficult for them to engage in passive heating, and how this might impact other areas of their life such as physical activity.

this study employs an interpretivist approach through semi-structured interviews to highlight participants' perceptions of and experiences with passive heating. to date, this topic has not been explored in-depth - this approach should bring nuance and context to light, aiding in future advocacy work which explores the potential of passive heating as a viable treatment for adults with t2dm. semi-structured interviews will be facilitated by an interview guide consisting of four main topic areas aiming to explore an individual's perception of and experience with passive heating as a treatment for t2dm and to ascertain whether engaging in this behaviour may affect physical activity. as no two conversations are ever the same, the approach to the interviews is one of flexibility through the use of open-ended questions and potential probes as the situation dictates - remaining open to following particular lines of participant thought. interviews will all be conducted by the principal investigator, mr thomas james, a doctoral researcher who has been trained in the required skills. he has also undertaken necessary training in good clinical practice and valid informed consent. interviews will be conducted virtually, by telephone or in person and will take place either at home or in a laboratory setting, dependent upon the individual's wishes. the interviews will be audio recorded and subsequently transcribed verbatim by a member of the research team. transcriptions will be analysed via thematic analysis to determine the main themes expressed by participants. all data analysis will be conducted by a trained member of the research team.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * willing and able to undertake the interview process * able to give informed consent exclusion criteria: * age \< 18 years * does not provide written informed consent * any neurological/psychiatric diagnoses * lack of fluency in english

Keywords: passive heating
effects of thoracic paravertebral block combined with s-ketamine on postoperative pain and cognitive function after thoracoscopic surgery

Conditions: Postoperative Cognitive Dysfunction

Summary: to investigate the effect of ultrasound-guided thoracic paravertebral nerve block combined with intraoperative infusion of s-ketamine on postoperative acute pain and cognitive function in patients with thoracoscopic surgery

a total of 120 patients who were admitted to qinhuangdao first hospital for and divided into control group (group c ), thoracic paravertebral nerve block combined with full anesthesia group (group ta), thoracic paravertebral nerve block combined with intraoperative infusion of s-ketamine group ( group te). 40 cases in each group. group c received general anesthesia, group ta received 0.375% ropivacaine 20ml thoracic paravertebral nerve block combined with general anesthesia under ultrasound guidance after anesthesia induction, and group te received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of ta group. anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation. the map(mean artery pressure) and hr(heart rate) of the three groups were recorded before surgery (t1), during the surgery (t2), immediately after surgery (t3). compare the vas（visual analogue scale）in the ten minuses after extubation and one day afte surgery .the cognitive function of the three groups were evaluated by the mini mental state scale (mmse) on one day before surgery , one day after surgery , and three months after surgery . compare the incidence of postoperative cognitive disfuntion（ pocd） among the three groups.

Eligibility criteria:
inclusion criteria: * 18-24kg/m2 * american society of anesthesiologists (asa) grades i-iii * the score of mini mental state examination≥24 exclusion criteria: * patients with heart, lung and other vital organ disorders * the score of mini mental state examination≤23 * preoperative psychiatric disorders or long-term use of drugs affecting the psychiatric system * have severe visual, hearing, speech impairment or other inability to communicate with the visitor * refuse to sign informed consent

Keywords: esketamine thoracic paravertebral block cognitive function
glutamine supplementation to prevent death or infection in extremely premature infants

Conditions: Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age; Infant, Premature; Sepsis

Summary: this large multicenter double-masked clinical trial tested whether supplementation of standard neonatal parenteral nutrition with glutamine would reduce the risk of death or late-onset sepsis in extremely-low-birth-weight (elbw, less than or equal to 1000 gm) infants. neonates with birth weights of 401-1000gm were randomized to standard trophamine or trophamine supplemented with glutamine before 72 hours and continued until the infants are tolerating full enteral feedings.

meeting the protein and energy requirements of extremely premature infants in early postnatal life requires early hyperalimentation and the gradual introduction of enteral feedings. glutamine, which is the most abundant amino acid in the human body and taken up in greatest quantity by the fetus from the placenta, is not routinely provided in neonatal parenteral nutrition preparations. this large multicenter double-masked clinical trial tested whether supplementation of standard neonatal parenteral nutrition with glutamine would reduce the risk of death or late-onset sepsis in extremely-low-birth-weight (elbw, less than or equal to 1000 gm) infants. neonates with birth weights of 401-1000gm were randomized to standard trophamine or trophamine supplemented with glutamine before 72 hours and continued until the infants are tolerating full enteral feedings. infants received a neurodevelopmental assessment by masked, certified examiners at 18-22 months postmenstrual age.

Eligibility criteria:
inclusion criteria: * 401-1000 gm * more than 12 hrs and less than 72 hrs after birth; intravenous access * parental consent exclusion criteria: * one or more major congenital anomalies * infants meeting criteria for terminal illness * congenital nonbacterial infection with overt signs at birth

Keywords: nichd neonatal research network extremely low birth weight (elbw) infants prematurity glutamine total parenteral nutrition nutrition very low birth weight (vlbw) infants
validation and testing of a novel continuous glucose and continuous ketone monitoring device in healthy volunteers

Conditions: Diabetes Ketoacidosis

Summary: diabetic ketoacidosis (dka) is a severe complication of type 1 diabetes (t1d) that can have life-threatening consequences. it occurs when there is a high level of glucose in the blood and the body produces excessive amounts of ketone bodies. to manage this condition, individuals with t1d need to constantly monitor their levels of ketone bodies and glucose. while continuous glucose monitoring (cgm) devices have made significant advancements in providing non-invasive or minimally invasive glucose measurements, there has been little progress in developing methods for continuous monitoring of ketone bodies (ckm). currently, the commonly used approaches involve self monitoring with commercially available blood or urine strips. however, these tools have limited adoption, provide only single time point measurements, and can be costly for some patients. in our project, which is funded by breakthrough t1d (2-sra-2022-1167-m-b), we address this challenge by utilizing a minimally invasive biosensor based on hydrogel microneedle (hmn). this biosensor enables simultaneous and continuous measurement of the primary biomarker for ketone formation, 3-β hydroxybutyrate (β-hb), as well as glucose levels. by doing so, we intend to reduce the risk of diabetic ketoacidosis in patients with t1d. we plan to test the developed cgm-ckm device on human subjects, including both healthy volunteers (hv) and patients with t1d. the hv testing will take place at the laboratory of dr. poudineh and dr. devries-aboud in waterloo, while the validation involving patients with t1d will be conducted in collaboration with dr. lal at stanford.


Eligibility criteria:
the age range for the healthy volunteers (hvs) will be between 18 and 45 years old and with no family history of diabetes (t1d or t2d, specifically biological parents and siblings). exclusion criteria included: (i) currently taking any medications (except for birth control for females); (ii) following a low-carbohydrate diet or consuming nutritional ketone supplements; (iii) considered competitive athlete engaged in competition or intensive training, (iv) have been diagnosed with diabetes (t1d or t2d), hypertension, cardiovascular disease, kidney disease, and thyroid disorder. (v) having an allergy to any of the ingredients in the products used in the study, which will be explained to you in detail.
an evaluation of patients access to their electronic medical records via the ipc connect application

Conditions: Solid Tumor; Hematologic Malignancy

Summary: the aim of our study is to investigate the effect of providing patients access to their electronic medical records via the ipc connect application on their a survey will be proposed to all outpatients with a solid or hematologic malignancy who will attend an appointement at institut paoli calmettes clinic. data will be collected during a 1-month period. the auto-questionnaire will be composed of 31 questions addressed to all patients, 17 questions will be specifically addressed to patients using ipc connect application and 7 questions will be addressed to patients who do not use the application.


Eligibility criteria:
inclusion criteria: * man or woman, age\> 18 years * solid tumor or hematologic malignancy * patient attending an appointment at institut paoli calmettes * non-opposition exclusion criteria: * emergency, vulnerable person or unable to provide informed consent * first appointment at institut paoli calmettes

Keywords: electronic medical records patients anxiety
antiviral drugs on the treatment of sars-cov-2

Conditions: Complication of Medical Care; Pneumonia, Viral

Summary: retrospective non-randomized analytical cohort study of completed sars-cov2 covid19 cases

analyzing the case histories of patients with sars-cov2 covid19 infection and the impact on the outcomes of prescribing antiviral drugs

Eligibility criteria:
inclusion criteria: main group * patients with covid19 with medium and easy condition disease * take favipiravir/remdisivir control group * patients with covid19 with medium and easy condition disease * not take favipiravir/remdisivir exclusion criteria: * patients younger 18 * severe conditionis